Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2016; 6(12):2141-2160. doi:10.7150/thno.16184 This issue Cite

Research Paper

A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor via Systemic Administration by Taking Advantages of the Limitation of EPR Effect

Yuting Yang1, Xiaowei Tai1, Kairong Shi1, Shaobo Ruan1, Yue Qiu1, Zhirong Zhang1, Bing Xiang2✉, Qin He1✉

1. Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of Pharmacy, Sichuan University, Block 3, 17 Southern Renmin Road, Chengdu 610041, P. R. China
2. Department of hematology, West China Hospital, Sichuan university, No. 17, Block 3, Southern Renmin Road, Chengdu 610041, P. R. China.

✉ Corresponding authors: Tel. /fax: +86 28 85502532. E-mail addresses: qinheedu.cn (Q. He), xiang7199com (B. Xiang).

Citation:
Yang Y, Tai X, Shi K, Ruan S, Qiu Y, Zhang Z, Xiang B, He Q. A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor via Systemic Administration by Taking Advantages of the Limitation of EPR Effect. Theranostics 2016; 6(12):2141-2160. doi:10.7150/thno.16184. https://www.thno.org/v06p2141.htm
Other styles

File import instruction

Abstract

Graphic abstract

The enhanced permeability and retention (EPR) effect has been comfortably accepted, and extensively assumed as a keystone in the research on tumor-targeted drug delivery system. Due to the unsatisfied tumor-targeting efficiency of EPR effect being one conspicuous drawback, nanocarriers that merely relying on EPR effect are difficult to access the tumor tissue and consequently trigger efficient tumor therapy in clinic. In the present contribution, we break up the shackles of EPR effect on nanocarriers thanks to their universal distribution characteristic. We successfully design a paclitaxel (PTX) and alpha-galactosylceramide (αGC) co-loaded TH peptide (AGYLLGHINLHHLAHL(Aib)HHIL-Cys) -modified liposome (PTX/αGC-TH-Lip) and introduce a new concept of immuno-chemotherapy combination via accumulation of these liposomes at both spleen and tumor sites naturally and simultaneously. The PTX-initiated cytotoxicity attacks tumor cells at tumor sites, meanwhile, the αGC-triggered antitumor immune response emerges at spleen tissue. Different to the case that liposomes are loaded with sole drug, in this concept two therapeutic processes effectively reinforce each other, thereby elevating the tumor therapy efficiency significantly. The data demonstrates that the PTX/αGC-TH-Lip not only possess therapeutic effect against highly malignant B16F10 melanoma tumor, but also adjust the in vivo immune status and induce a more remarkable systemic antitumor immunity that could further suppress the growth of tumor at distant site. This work exhibits the capability of the PTX/αGC-TH-Lip in improving immune-chemotherapy against tumor after systemic administration.

Keywords: Liposome, Distribution characteristic, Paclitaxel, Alpha-galactosylceramide, Cancer immune-chemotherapy.

Citation styles

APA
Yang, Y., Tai, X., Shi, K., Ruan, S., Qiu, Y., Zhang, Z., Xiang, B., He, Q. (2016). A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor via Systemic Administration by Taking Advantages of the Limitation of EPR Effect. Theranostics, 6(12), 2141-2160. https://doi.org/10.7150/thno.16184.

ACS
Yang, Y.; Tai, X.; Shi, K.; Ruan, S.; Qiu, Y.; Zhang, Z.; Xiang, B.; He, Q. A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor via Systemic Administration by Taking Advantages of the Limitation of EPR Effect. Theranostics 2016, 6 (12), 2141-2160. DOI: 10.7150/thno.16184.

NLM
Yang Y, Tai X, Shi K, Ruan S, Qiu Y, Zhang Z, Xiang B, He Q. A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor via Systemic Administration by Taking Advantages of the Limitation of EPR Effect. Theranostics 2016; 6(12):2141-2160. doi:10.7150/thno.16184. https://www.thno.org/v06p2141.htm

CSE
Yang Y, Tai X, Shi K, Ruan S, Qiu Y, Zhang Z, Xiang B, He Q. 2016. A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor via Systemic Administration by Taking Advantages of the Limitation of EPR Effect. Theranostics. 6(12):2141-2160.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use